Novo Nordisk Net Long-Term Debt 2010-2024 | NVO
Novo Nordisk annual/quarterly net long-term debt history and growth rate from 2010 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Novo Nordisk net long-term debt for the quarter ending December 31, 2024 was $10.593B, a 5073.11% decline year-over-year.
- Novo Nordisk net long-term debt for the twelve months ending December 31, 2024 was $8.920B, a 1668.79% decline year-over-year.
- Novo Nordisk annual net long-term debt for 2024 was $10.593B, a 5073.11% decline from 2023.
- Novo Nordisk annual net long-term debt for 2023 was $-0.213B, a 37.53% decline from 2022.
- Novo Nordisk annual net long-term debt for 2022 was $-0.341B, a 113.85% decline from 2021.
Novo Nordisk Annual Net Long-Term Debt
(Millions of US $) |
| 2024 |
$10,593 |
| 2023 |
$-213 |
| 2022 |
$-341 |
| 2021 |
$2,461 |
| 2020 |
$725 |
| 2019 |
$-111 |
| 2018 |
$14 |
| 2017 |
$N/A |
| 2016 |
$N/A |
| 2015 |
$N/A |
| 2014 |
$N/A |
| 2013 |
$N/A |
| 2012 |
$-87 |
| 2011 |
$N/A |
| 2010 |
$N/A |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$310.672B |
$42.122B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
